12/20

2024

Qingfeng Pharmaceutical Group will attend “The 43rd Annual J.P. Morgan Healthcare Conference” in San Francisco, from January 13-16, 2025. Qingfeng would like to hold one-on-one meetings ...

07/08

2024

On June 28, the Eribulin Mesilate Injection developed by Qingfeng Pharmaceutical Group was approved for marketing by the U.S. Food and Drug Administration (FDA), making Qingfeng Pharmaceutical the ...

07/06

2024

On June 28, the Brivaracetam tablets (trade name: Qingruitan®) developed by Qingfeng Pharmaceutical Group were officially approved for marketing by the National Medical Products Administration. The...
NEWS
R&D

Innovation Platform

R&D Talents

R&D Results

Research Cooperation
Qingfeng Pharmaceutical Group Co.Ltd
Location:8 Zhandong Av., Zhanggong, Ganzhou, Jiangxi Province, China
Phone:+86-0797-5560800,5560600 Fax: +86-0797-5560620